784. Clinical and Economic Burden of Pneumococcal Disease in Adults 19-64 Years with Chronic Conditions in the United States
Session: Poster Abstract Session: Vaccines: Pneumococcal
Thursday, October 27, 2016
Room: Poster Hall
  • kavaspet_192273-0001-ID_Week_Poster-1_Chronic_v1.02.pdf (329.0 kB)
  • Background:

    Adults < 65 years with chronic conditions are at high risk for pneumococcal infection. Limited studies have examined both the clinical and economic burden of pneumococcal disease in this population. We assessed pneumococcal disease rates, resource utilization and costs in US adults < 65 years with chronic conditions indicated for pneumococcal vaccination by ACIP.


    A retrospective cohort study using medical and pharmacy claims from MarketScan Commercial Claims database (2012-2014) was conducted to compare rates and cost of all-cause pneumonia, pneumococcal pneumonia and invasive pneumococcal disease (IPD) in immunocompetent older adults 19-64 years with and without chronic conditions. Conditions of interest were diabetes, chronic heart, liver and lung disease, and asthma. Immunocompromised patients were excluded.


    35.7 million adults 19-64 years old were included in the analysis. 83% had no condition; 7.2% had diabetes, 3.0% chronic heart disease, 3.0% asthma, 2.1% chronic lung disease, and 1.3% chronic liver disease.

    Adults with chronic conditions had 3.4, 3.7 and 6.9 times the rate of all-cause, pneumococcal pneumonia, and IPD compared to healthy adults respectively. IPD rates were highest in chronic heart and diabetes patients.

    Per IPD episode, adults with chronic conditions had slightly more hospital visits and longer length of stay compared to healthy adults - 0.7 vs. 0.6 visits and 4.8 vs 3.7 days respectively, but substantially higher costs ($25,380 vs. $19,551). IPD costs were highest in chronic liver disease patients ($32,173).


    Adults aged 19-64 years with chronic conditions are at high risk of pneumococcal disease, consume more healthcare resources and incur greater costs.

    H. Keri Yang, PhD, MPH, MS, Merck & Co., Inc, Center for Observational and Real-World Evidence, Kenilworth, NJ, Dongmu Zhang, PhD, Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, Panagiotis Mavros, PhD, Merck & Co. Inc, Center for Observational and Real-World Evidence, Kenilworth, NJ and Tanaz Petigara, PhD, Merck & Co., Inc., Center for Observational and Real-World Evidence, Kenilworth, NJ


    H. K. Yang, Merck & Co: Employee , Salary

    D. Zhang, Merck & Co: Employee , Salary

    P. Mavros, Merck & Co: Employee , Salary

    T. Petigara, Merck & Co: Employee , Salary

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.